Drug · CHEMBL1908361
LEVOLEUCOVORIN CALCIUM
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. LEVOLEUCOVORIN CALCIUM. Drugs and targets, record CHEMBL1908361. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1908361
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
CL 307,782, CL-307782, Calcium (6s)-folinate, Calcium levofolinate, Calcium levofolinate (6s,l), Calcium levofolinate hydrate, Calcium levofolinate pentahydrate, Elvorine, Folinic acid l-form calcium salt, Isovorin, Levofolinate calcium, Levofolinate de calcium, Levofolinato de calcio
- ChEMBL
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases13
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| colorectal cancer | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0005575 |
| colorectal carcinoma | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0024331 |
| esophageal squamous cell carcinoma | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005580 |
| gastric cancer | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0001056 |
| hepatocellular carcinoma | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0007256 |
| malignant colon neoplasm | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0021063 |
| malignant pancreatic neoplasm | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0009831 |
| metastatic colorectal cancer | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=EFO_1001480 |
| pancreatic ductal adenocarcinoma | Phase 1 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005184 |
| pancreatic neoplasm | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0021040 |
1 to 10 of 13Source Open Targets
See all 13 diseasesTrials11
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02394795 | Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC | Phase 3 | 823 | 2023-11-01 | levofolinate calcium | Its name | ClinicalTrials.gov |
| NCT02337946 | Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma | Phase 2 | 164 | 2019-03-01 | levofolinate calcium | Its name | ClinicalTrials.gov |
| NCT00195585 | Study Evaluating Isovorin in Colon Cancer | Phase 3 | 650 | isovorin | Its name | ClinicalTrials.gov | |
| NCT04776655 | Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB | Phase 3 | 280 | calcium levofolinate | Its name | ClinicalTrials.gov | |
| NCT00195572 | Study Evaluating Isovorin in Advanced/Recurrent Gastric Cancer | Phase 3 | 200 | isovorin | Its name | ClinicalTrials.gov | |
| NCT02697058 | Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer | Phase 2 | 84 | levoleucovorin calcium | Its name | ClinicalTrials.gov | |
| NCT02497157 | Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer | Phase 2 | 45 | levofolinate calcium | Its name | ClinicalTrials.gov | |
| NCT05546853 | Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 | 43 | calcium levofolinate | Its name | ClinicalTrials.gov | |
| NCT06607107 | mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria | Phase 2 | 29 | calcium levofolinate | Its name | ClinicalTrials.gov | |
| NCT03301454 | Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer | Phase 2 | 15 | calcium levofolinate | Its name | ClinicalTrials.gov |
1 to 10 of 11
See all 11 trialsComparisons in its trials6
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Group P; mFOLFOX6 + Panitumumab Combination Therapy vs Group B; mFOLFOX6 + Bevacizumab Combination Therapy: Number of Participants With Treatment-emergent Adverse Events (TEAE) | 402 of 404 | 398 of 407 | 811 | NCT02394795 | Trial comparisons |
| Group P; mFOLFOX6 + Panitumumab Combination Therapy vs Group B; mFOLFOX6 + Bevacizumab Combination Therapy: deaths from any cause | 14 of 404 | 9 of 407 | 811 | NCT02394795 | Trial comparisons |
| Group P; mFOLFOX6 + Panitumumab Combination Therapy vs Group B; mFOLFOX6 + Bevacizumab Combination Therapy: serious adverse events | 115 of 404 | 95 of 407 | 811 | NCT02394795 | Trial comparisons |
| Group P; mFOLFOX6 + Panitumumab Combination Therapy vs Group B; mFOLFOX6 + Bevacizumab Combination Therapy: Number of Participants Treated With Curative Surgical Resection After Chemotherapy | 66 of 400 | 44 of 402 | 802 | NCT02394795 | Trial comparisons |
| Group A vs Group B: deaths from any cause | 2 of 56 | 0 of 54 | 110 | NCT02337946 | Trial comparisons |
| Group A vs Group B: serious adverse events | 20 of 56 | 18 of 54 | 110 | NCT02337946 | Trial comparisons |
Papers from its trials5
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1908361
GET https://conductscience.org/api/drugs/v1/CHEMBL1908361/targets